You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. STTR Phase I:Mechanically Controlled Drug Delivery Platform for Joint Environments

    SBC: George Dodge            Topic: BM

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project seeks to address the strong clinical need for a single injection/dose sparing delivery system that can safely release therapeutics in the joint space over time in a controllable dosing manner for sustained symptomatic relief. Early and efficient treatments that mitigate inflammation are becomi ...

    STTR Phase I 2023 National Science Foundation
  2. Semiconductor Device Simulation Software with Monte Carlo Based Thermal Transport Modeling

    SBC: ADVANCED COOLING TECHNOLOGIES INC            Topic: C5501b

    Current semiconductor device simulation software adopts Fourier’s law to perform the thermal transport modeling. However, Fourier’s law will become invalid at micro/nano-scale, which can cause a large discrepancy in the thermal and electrical performance between the simulation results and the actual application. To improve the current state-of-the-art, a new semiconductor device simulation sof ...

    STTR Phase I 2023 Department of Energy
  3. Direct Air Capture by Ion-Exchange Sorbent and Low-Grade Heat

    SBC: ADVANCED COOLING TECHNOLOGIES INC            Topic: C5422a

    Anthropogenic CO2 emissions are widely accepted as the primary driver of global climate change, leading to many adverse outcomes for humanity. While CO2 emissions are equally distributed within the atmosphere, the negative impacts of human-induced climate change are not, with marginalized people suffering the worst. While renewable energy technologies can reduce future emissions, large-scale atmos ...

    STTR Phase II 2023 Department of Energy
  4. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of recombinant VSV vaccines for emerging bunyaviruses

    SBC: Advac Therapeutic LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Emerging viral infections remain a global threat to human health. Bunyaviruses are the largest order of RNA viruses that includes many clinically relevant human pathogens such as Lassa, Rift Valley Fever and various hantaviruses which cause viral hemorrhagic fever (VHF). SFTSV, or Severe fever with thrombocytopenia syndrome virus, is an emerging tick-borne bunyavirus that ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. TeleLine: Plug-n-Play Inline Respiratory Remote Data Acquisition System

    SBC: OMNIBUS MEDICAL DEVICES, LLC            Topic: NINR

    Project Summary One in five Americans live in a rural community served by rural hospitals yet only 1% of ICU resources are available to these hospitals. When the level of care required by a patient exceeds the capabilities of the admitting hospital, the patient is transferred to a better-equipped tertiary hospital. Approximately 800,000 patients require mechanical ventilation every year in the Uni ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease

    SBC: FURANICA, INC.            Topic: NHLBI

    1 Project Summary2 Cardiovascular risks in dyslipidemia patients are commonly controlled by lowering the LDL-C level using statins.3 However, a significant residual cardiovascular risk persists in patients with additional concurrent risk factors such4 as obesity, diabetes, insulin resistance, and elevated triglyceride-rich lipoproteins. Given the multifaceted5 underlying pathology of cardiovascula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone

    SBC: Altrumed LLC            Topic: NIDA

    ABSTRACT / PROJECT SUMMARY Despite the wide availability of the antidote naloxone, fatal opioid overdoses still occur at a rate of ~50-70,000 / year in the US. The problem is that naloxone requires a bystander to find and diagnose the overdose, find someone who has naloxone, and then properly administer it. Unfortunately, if this does not occur within 5 minutes, the patient will suffer from brain ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Optimizing the synthesis of[18F]FTMP for commercial distribution

    SBC: VELLUM BIOSCIENCES LLC            Topic: NIBIB

    Abstract The development of genetic medicines such as gene and cell therapies like Chimeric Antigen Receptor (CAR) T cells has necessitated new technologies that can monitor the biodistribution of these therapies in human patients. Imaging is particularly well suited to provide such quantitative measurements of a genetic medicine over time. Vellum Biosciences is a platform imaging company geared t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk

    SBC: MOLECULAR TARGETING TECHNOLOGIES, INC.            Topic: NHLBI

    We propose to develop a novel antithrombotic agent with improved efficacy and safety over standard of care via the following properties: 1) specific targeting to procoagulant surfaces, 2) high coagulant site binding and blocking capacity, 3) potent and specific effects of reducing clot size by selectively blocking only highly coagulant sites, 4) reducing bleeding risk compared with current antipla ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government